Abridge Expands Ambient AI Platform With Eli Lilly Investment and NVIDIA Partnership
Abridge, a health-tech startup, announced a strategic investment from drugmaker Eli Lilly and the launch of an AI-native clinician intelligence platform on Thursday in New York City. According to co-founder Dr. Shiv Rao, the system moves beyond transcription to automate billing, clinical decision support, and pharmaceutical trial screening for more than 300 health systems, including Johns Hopkins, Emory Healthcare, and Northwestern Medicine.
How does the Abridge AI platform work in clinical settings?
The platform captures doctor-patient conversations in real time to generate clinical notes, billing codes, and patient summaries before a physician leaves the room. According to the company, the technology also surfaces care gaps and prior clinical context before a visit begins.
During patient encounters, the system suggests discussion topics and displays relevant clinical guidelines without requiring the doctor to switch applications. Post-visit, it generates orders and flowsheets based on the spoken words of the encounter.
Abridge currently supports over 100 million clinical conversations annually and serves more than 250 million patients, according to company data.
What are the strategic partnerships with NVIDIA and Eli Lilly?
NVIDIA and Abridge are co-developing a foundation model specifically trained on the dynamics of doctor-patient dialogue, rather than adapting a general large language model for medical use. Abridge also partnered with Artisight, an NVIDIA-backed company, to integrate computer vision for patient monitoring and nursing workflows.
The investment from Eli Lilly aligns with the pharmaceutical company’s development of an AI supercomputer in partnership with NVIDIA. Rao told Fortune that a primary priority for the collaboration is using Abridge’s life sciences module to identify clinical trial eligibility during patient conversations.
Who are the main competitors in the ambient AI market?
Microsoft is the dominant enterprise incumbent after acquiring the speech-recognition firm Nuance for $19.7 billion in 2022. Other well-capitalized challengers include Nabla, Suki, and Ambience Healthcare.
The ambient clinical intelligence market was valued at $7.24 billion in 2025 and is projected to reach $56.61 billion by 2035. Industry expectations suggest the field may consolidate within the next 12 to 18 months.
What are the risks associated with clinical AI documentation?
The expansion of the platform increases its “risk surface,” as recording protected health conversations requires business associate agreements, state-specific patient consent, and updated security assessments.
There is also a liability risk if AI-generated notes bypass physician review and enter the permanent medical record. This risk could compound as the system begins generating billing codes and clinical orders.
Frequently Asked Questions
What is the primary goal of the new AI-native clinician intelligence platform?
The platform aims to connect healthcare stakeholders by using patient-clinician conversations as the foundation for billing, clinical decision support, payer adjudication, and pharmaceutical trial screening.
Which health systems currently use Abridge?
More than 300 health systems use the platform, including Northwestern Medicine, Emory Healthcare, and Johns Hopkins.
How does Abridge differ from general AI models?
Through a partnership with NVIDIA, Abridge is developing a foundation model trained specifically on the dynamics of doctor-patient dialogue instead of using a general large language model adapted for medicine.
Do you believe AI-generated clinical notes will improve the patient experience or increase medical liability?